Independent Phase I CBOI operates as the only independent, dedicated Phase I cancer center on the East Coast, signaling a unique early clinical trial access point for sponsors seeking Specialized early-phase immunotherapy collaborations and rapid patient enrollment.

Early Trial Scale With over 100 early phase clinical trials and a track record of treating nearly 4,000 cancer patients, CBOI demonstrates a strong clinical execution capability and a proven platform for advancing novel cell therapies that may attract sponsors seeking evidence of feasibility and patient impact.

Integrated BioCytics The in-house BioCytics organization covers research, process development, cGMP manufacturing, regulatory, and operations, offering a potential one-stop-shop for sponsors looking to streamline translational work, reduce vendor coordination, and accelerate timelines.

Collaborative Potential Historical collaboration with Xcell Biosciences for pre-clinical enrichment highlights openness to partnering with technology and cell therapy innovators, suggesting opportunities for co-development, technology transfer, or joint optimization of immunotherapy platforms.

Regional Access Hub As a regional referral hub for Phase I access in a community setting, CBOI can serve as a scalable site network for sponsor-driven studies targeting diverse patient populations and faster screening, enabling expansion of trial reach beyond major academic centers.